amlodipine has been researched along with Atrial Fibrillation in 16 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compared the effect of antihypertensive treatment with valsartan or ramipril on atrial fibrillation (AF) recurrence, on P-wave dispersion, (PWD) and on serum procollagen type I carboxy terminal peptide (PIP)." | 9.13 | Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. ( Corradi, L; Derosa, G; Ferrari, I; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 9.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "The aim of the study was to evaluate the effect of losartan as compared with amlodipine, both associated with amiodarone, in preventing the recurrence of atrial fibrillation (AF) in hypertensive patients with a history of recent paroxysmal atrial fibrillation." | 9.12 | Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. ( Corradi, L; Destro, M; Fogari, E; Fogari, R; Mugellini, A; Rinaldi, A; Zoppi, A, 2006) |
| "Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients." | 7.96 | Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. ( Bahteeva, D; Bochkov, P; Cherniaeva, M; Golovina, O; Gorbatenkova, S; Kulikova, M; Mirzaev, K; Ostroumova, O; Rytkin, E; Shevchenko, R; Sychev, D, 2020) |
| "To assess effect of calcium antagonists amlodipine and verapamil on the risk of development of atrial fibrillation after coronary artery bypass surgery." | 7.72 | [Effect of calcium antagonists verapamil and amlodipine on the risk of development of atrial fibrillation after coronary artery bypass grafting]. ( Afanas'ev, SA; Akhmedov, ShD; Antonchenko, IV; Dzhavadova, GK; Evtushenko, AV; Kandinskiĭ, ML; Kozlov, BN; Popov, SV; Shipulin, VM; Vecherskiĭ, IuIu, 2003) |
| "Telmisartan was more effective than amlodipine in preventing AF recurrences in hypertensive patients with paroxysmal AF." | 6.77 | Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2012) |
| " We sought to determine whether randomization to lisinopril reduces incident AF or atrial flutter (AFL) compared with chlorthalidone in a large clinical trial cohort with extended post-trial surveillance." | 5.24 | Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). ( Albert, CM; Alonso, A; Davis, BR; Dewland, TA; Haywood, LJ; Marcus, GM; Simpson, LM; Soliman, EZ; Yamal, JM, 2017) |
| "The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is an open-label randomized comparison between an ARB (candesartan) and a CCB (amlodipine) in the treatment of paroxysmal AF associated with hypertension." | 5.15 | Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). ( Aizawa, Y; Atarashi, H; Fukatani, M; Hirai, M; Hirayama, A; Inoue, H; Kamakura, S; Kato, T; Kodama, I; Koretsune, Y; Kumagai, K; Kurachi, Y; Mitamura, H; Nakaya, H; Ogawa, S; Ohe, T; Ohtsu, H; Okumura, K; Saikawa, T; Sakurai, M; Sato, T; Sugi, K; Watanabe, E; Yamashita, T; Yamazaki, T, 2011) |
| "This study compared the effect of antihypertensive treatment with valsartan or ramipril on atrial fibrillation (AF) recurrence, on P-wave dispersion, (PWD) and on serum procollagen type I carboxy terminal peptide (PIP)." | 5.13 | Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. ( Corradi, L; Derosa, G; Ferrari, I; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 5.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "The aim of the study was to evaluate the effect of losartan as compared with amlodipine, both associated with amiodarone, in preventing the recurrence of atrial fibrillation (AF) in hypertensive patients with a history of recent paroxysmal atrial fibrillation." | 5.12 | Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. ( Corradi, L; Destro, M; Fogari, E; Fogari, R; Mugellini, A; Rinaldi, A; Zoppi, A, 2006) |
| "The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension." | 5.12 | Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension. ( Aizawa, Y; Atarashi, H; Fukatani, M; Hirai, M; Hirayama, A; Inoue, H; Kamakura, S; Kato, T; Kodama, I; Koretsune, Y; Kumagai, K; Kurachi, Y; Mitamura, H; Nakaya, H; Ogawa, S; Ohe, T; Ohtsu, H; Okumura, K; Saikawa, T; Sakurai, M; Sugi, K; Watanabe, E; Yamashita, T; Yamazaki, T, 2006) |
| "Objectives For revealing the peculiarities of the drug-drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil - inhibitor CYP3A4 and P-gp and amlodipine - substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients." | 3.96 | Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. ( Bahteeva, D; Bochkov, P; Cherniaeva, M; Golovina, O; Gorbatenkova, S; Kulikova, M; Mirzaev, K; Ostroumova, O; Rytkin, E; Shevchenko, R; Sychev, D, 2020) |
| "Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto (SILK study) is a prospective, multicenter, randomized, and open-label comparative evaluation of the effects of irbesartan and amlodipine on AF recurrence in hypertensive patients with AF who are scheduled to undergo catheter ablation or electrical cardioversion of AF." | 3.88 | Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study). ( Fujimoto, K; Iwasa, A; Kaikita, K; Kajiwara, I; Koyama, J; Matsui, K; Matsumura, T; Morihisa, K; Morikami, Y; Ogawa, H; Tsujita, K; Tsunoda, R; Uemura, T; Yamabe, H, 2018) |
| "To assess effect of calcium antagonists amlodipine and verapamil on the risk of development of atrial fibrillation after coronary artery bypass surgery." | 3.72 | [Effect of calcium antagonists verapamil and amlodipine on the risk of development of atrial fibrillation after coronary artery bypass grafting]. ( Afanas'ev, SA; Akhmedov, ShD; Antonchenko, IV; Dzhavadova, GK; Evtushenko, AV; Kandinskiĭ, ML; Kozlov, BN; Popov, SV; Shipulin, VM; Vecherskiĭ, IuIu, 2003) |
| "Telmisartan was more effective than amlodipine in preventing AF recurrences in hypertensive patients with paroxysmal AF." | 2.77 | Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2012) |
| "Valsartan-based treatment reduced the development of new-onset AF, particularly sustained AF in hypertensive patients, compared with amlodipine-based therapy." | 2.73 | Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. ( Hua, TA; Julius, S; Kjeldsen, SE; McInnes, GT; Schmieder, RE; Zanchetti, A, 2008) |
| "Hypertension is the most prevalent and potentially modifiable risk factor for AF." | 2.72 | Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis. ( Feng, J; Gan, Y; Jiang, H; Ma, H, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sychev, D | 1 |
| Mirzaev, K | 1 |
| Cherniaeva, M | 1 |
| Kulikova, M | 1 |
| Bochkov, P | 1 |
| Shevchenko, R | 1 |
| Gorbatenkova, S | 1 |
| Golovina, O | 1 |
| Ostroumova, O | 1 |
| Bahteeva, D | 1 |
| Rytkin, E | 1 |
| Ma, H | 1 |
| Jiang, H | 1 |
| Feng, J | 1 |
| Gan, Y | 1 |
| Yamabe, H | 1 |
| Kaikita, K | 1 |
| Matsumura, T | 1 |
| Iwasa, A | 1 |
| Koyama, J | 1 |
| Uemura, T | 1 |
| Morikami, Y | 1 |
| Tsunoda, R | 1 |
| Morihisa, K | 1 |
| Fujimoto, K | 1 |
| Kajiwara, I | 1 |
| Matsui, K | 1 |
| Tsujita, K | 1 |
| Ogawa, H | 1 |
| Dewland, TA | 1 |
| Soliman, EZ | 2 |
| Yamal, JM | 1 |
| Davis, BR | 2 |
| Alonso, A | 1 |
| Albert, CM | 1 |
| Simpson, LM | 2 |
| Haywood, LJ | 2 |
| Marcus, GM | 1 |
| Piller, LB | 1 |
| Ghosh, A | 1 |
| Einhorn, PT | 1 |
| Ford, CE | 1 |
| Probstfield, JL | 1 |
| Wright, JT | 1 |
| Kario, K | 1 |
| Hoshide, S | 1 |
| Uchiyama, K | 1 |
| Yoshida, T | 1 |
| Okazaki, O | 1 |
| Noshiro, T | 1 |
| Aoki, H | 1 |
| Mizuno, H | 1 |
| Matsumoto, Y | 1 |
| Fogari, R | 4 |
| Derosa, G | 3 |
| Ferrari, I | 1 |
| Corradi, L | 3 |
| Zoppi, A | 4 |
| Lazzari, P | 2 |
| Santoro, T | 1 |
| Preti, P | 3 |
| Mugellini, A | 4 |
| Yamashita, T | 2 |
| Inoue, H | 2 |
| Okumura, K | 2 |
| Kodama, I | 2 |
| Aizawa, Y | 2 |
| Atarashi, H | 2 |
| Ohe, T | 2 |
| Ohtsu, H | 2 |
| Kato, T | 2 |
| Kamakura, S | 2 |
| Kumagai, K | 2 |
| Kurachi, Y | 2 |
| Koretsune, Y | 2 |
| Saikawa, T | 2 |
| Sakurai, M | 2 |
| Sato, T | 1 |
| Sugi, K | 2 |
| Nakaya, H | 2 |
| Hirai, M | 2 |
| Hirayama, A | 2 |
| Fukatani, M | 2 |
| Mitamura, H | 2 |
| Yamazaki, T | 2 |
| Watanabe, E | 2 |
| Ogawa, S | 2 |
| Goette, A | 1 |
| Maffioli, P | 1 |
| Perrone, T | 1 |
| Popov, SV | 1 |
| Kandinskiĭ, ML | 1 |
| Kozlov, BN | 1 |
| Antonchenko, IV | 1 |
| Evtushenko, AV | 1 |
| Dzhavadova, GK | 1 |
| Vecherskiĭ, IuIu | 1 |
| Akhmedov, ShD | 1 |
| Afanas'ev, SA | 1 |
| Shipulin, VM | 1 |
| Destro, M | 1 |
| Fogari, E | 1 |
| Rinaldi, A | 1 |
| Higashide, T | 1 |
| Okai, T | 1 |
| Yoshida, S | 1 |
| Tonoike, N | 1 |
| Kakihara, M | 1 |
| Mizumura, T | 1 |
| Oshima, A | 1 |
| Sugimura, Y | 1 |
| Tamamura, T | 1 |
| Ogata, I | 1 |
| Schmieder, RE | 1 |
| Kjeldsen, SE | 1 |
| Julius, S | 1 |
| McInnes, GT | 1 |
| Zanchetti, A | 1 |
| Hua, TA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing[NCT01748253] | 80 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amlodipine and Atrial Fibrillation
| Article | Year |
|---|---|
Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibri | 2021 |
10 trials available for amlodipine and Atrial Fibrillation
| Article | Year |
|---|---|
Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; Chlorthalidone; Double-Bli | 2017 |
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; C | 2018 |
Dose Timing of an Angiotensin II Receptor Blocker/Calcium Channel Blocker Combination in Hypertensive Patients With Paroxysmal Atrial Fibrillation.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Benzoates; | 2016 |
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Double-Blind Method; Electrocardiogr | 2008 |
Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biph | 2011 |
Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrial Fibrilla | 2012 |
Losartan and prevention of atrial fibrillation recurrence in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Double-Blind Method; Female; | 2006 |
Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl C | 2006 |
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillat | 2008 |
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Bl | 2008 |
5 other studies available for amlodipine and Atrial Fibrillation
| Article | Year |
|---|---|
Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation.
Topics: Aged, 80 and over; Amlodipine; Atrial Fibrillation; Calcium Channel Blockers; Cross-Sectional Studie | 2020 |
Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study).
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Atrial Fibrillation; Biphenyl Compounds; Blood P | 2018 |
The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl C | 2011 |
[Effect of calcium antagonists verapamil and amlodipine on the risk of development of atrial fibrillation after coronary artery bypass grafting].
Topics: Adult; Aged; Amlodipine; Atrial Fibrillation; Calcium Channel Blockers; Coronary Artery Bypass; Huma | 2003 |
[Basedow disease with recurrent syncopal attack and severe pulmonary hypertension].
Topics: Aged; Amlodipine; Atrial Fibrillation; Digoxin; Female; Graves Disease; Humans; Hypertension, Pulmon | 2007 |